FG-3246 shows promising results in phase 1 trial

[Maxone73]

As mono therapy "data from the study showed that 36% of evaluable patients experienced at least a 50% reduction in prostate-specific antigen (PSA) levels from baseline. Among RECIST-evaluable patients, 20% demonstrated a partial response or a reduction in tumor size of at least 30%. The median duration of response was 7.5 months.

Among all patients, the median radiographic progression-free survival (rPFS) was 8.7 months."

urologytimes.com/view/fg-32...

[janebob99]

Thank you for sharing that study.

Interestingly, the use of Dutasteride (0.5 mg/day) achieves the exact same reduction in PSA (50%) and reduction in tumor volume (30% ), and is currently FDA approved. It's typically used to treat male pattern baldness, but many large randomized, placebo-controlled studies have proven its effectiveness against prostate cancer.

[Maxone73 in reply to janebob99]

Create a post just for the use of dutasteride in mCRPC and paste all the links to such studies there please. So we can build something like a reference book to help people to give info to their MOs!

[janebob99 in reply to Maxone73]

Great suggestion. I will do that!

[Maxone73 in reply to janebob99]

I must start doing the same, thee amount of info is getting out of control!